Simon Friedensohn
About Simon Friedensohn
Simon Friedensohn serves as the Director of Machine Learning & Data Engineering at Alloy Therapeutics, where he integrates machine learning and data engineering to advance drug discovery. He holds a PhD in Biotechnology from ETH Zürich and has a strong background in developing data-driven solutions for biotechnology applications.
Work at Alloy Therapeutics
Simon Friedensohn serves as the Director of Machine Learning & Data Engineering at Alloy Therapeutics, a role he has held since 2022. In this position, he integrates machine learning and data engineering to enhance drug discovery processes. He has played a pivotal role in establishing machine learning frameworks that support collaborative scientific research within the biotechnology ecosystem. His contributions focus on developing data-driven solutions aimed at improving therapeutic outcomes.
Education and Expertise
Simon Friedensohn has an extensive educational background in biotechnology. He is currently pursuing a Master of Science in Biotechnology, Systems Biology at ETH Zürich, having started in 2015. He also completed his Doctor of Philosophy (PhD) in Biotechnology at the same institution from 2015 to 2020. Additionally, he earned a Bachelor of Science (BS) in Biotechnology from ETH Zürich, beginning his studies in 2012. His academic training underpins his expertise in developing solutions for biotechnology applications.
Background
Before joining Alloy Therapeutics, Simon Friedensohn co-founded deepCDR Biologics, where he worked from 2019 to 2022. He also gained experience as a Research Intern at Roche in the pRED, Genetics & Genomics division for eight months in 2014. His roles in these organizations contributed to his understanding of the biotechnology landscape and the application of machine learning in drug development.
Achievements
Throughout his career, Simon Friedensohn has contributed significantly to the biotechnology field, particularly in the integration of machine learning into drug discovery. His work at Alloy Therapeutics has been instrumental in enhancing collaborative scientific research. Additionally, his involvement in the establishment of machine learning frameworks demonstrates his commitment to advancing therapeutic outcomes through innovative data-driven approaches.